This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cerner's CommunityWorks Picked by Reeves County Hospital
by Zacks Equity Research
Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Becton, Dickinson (BD) is likely to gain from expansion into emerging overseas markets.
Abbott Banks on New Approvals and Buyouts, Competition Rife
by Zacks Equity Research
Abbott's (ABT) receipt of FDA approval for XIENCE Sierra coronary stent system as well as a reimbursement approval in Japan for the same device will help it revive the dull Vascular business.
Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global
by Zacks Equity Research
Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.
Cerner Integrated Platform Implemented by Spectrum Health
by Zacks Equity Research
Spectrum Health selects Cerner's (CERN) Cerner Integrated Platform to treat psychological disorders.
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
by Zacks Equity Research
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.
Here's Why You Should Hold AngioDynamics' (ANGO) Stock Now
by Zacks Equity Research
AngioDynamics (ANGO) to benefit from a solid product portfolio. However, the company???s core Peripheral Vascular business has been sluggish.
Veeva's Vault CDMS to Unify Clinical Data in Single Platform
by Zacks Equity Research
Veeva's (VEEV) cloud-based applications' market prospects bright.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
by Zacks Equity Research
ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.
QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers
by Zacks Equity Research
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
Cooper's MiSight Lens Effective in Checking Juvenile Myopia
by Zacks Equity Research
Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.
Can Intuitive Surgical (ISRG) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
by Zacks Equity Research
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio
by Zacks Equity Research
QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
by Zacks Equity Research
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.
Omnicell Continues to Pursue Buyouts, Costs on the Rise
by Zacks Equity Research
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
Cardiovascular Systems Portfolio Strong, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
Veeva Gains as MD&D Companies Pick Its Cloud-Based Services
by Zacks Equity Research
Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.
Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.
3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare
by Sreyoshi Mukherjee
Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.